Ewa Parfieniuk

Ewa Parfieniuk

Auto-generated profile, based on publicly available information

Ewa Parfieniuk

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Food Chemistry
Verified
Journal Article
Closed access
ASAneta Sławińska
Aneta Sławińska
EFEmilia Fornal
Emilia Fornal
WRWojciech Radzki
Wojciech Radzki
KSKatarzyna Skrzypczak
Katarzyna Skrzypczak
MZMarta Zalewska-Korona
Marta Zalewska-Korona
ASAnna Stachniuk
Anna Stachniuk

19 January 2018 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
KPKarolina Pietrowska
Karolina Pietrowska
DDDiana Anna Dmuchowska
Diana Anna Dmuchowska
PKPawel Krasnicki
Pawel Krasnicki
ABAleksandra Bujalska
Aleksandra Bujalska
PSPaulina Samczuk
Paulina Samczuk
Michal CiborowskiMichal Ciborowski
Michal Ciborowski

20 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MZMonika Zbucka-Krętowska
Monika Zbucka-Krętowska
MNMagdalena Niemira
Magdalena Niemira
MPMagdalena Paczkowska-Abdulsalam
Magdalena Paczkowska-Abdulsalam
Agnieszka BielskaAgnieszka Bielska
Agnieszka Bielska
ASAnna Szalkowska
Anna Szalkowska
AKAdam Krętowski
Adam Krętowski
The altered expression pattern of miRNAs might potentially reflect anomalies related to foetal chromosomal aberrations. The aim of the study was to determine the expression level of miRNAs in plasma of pregnant women with foetal Down syndrome (DS). Out of 198 amniocentesis performed at 15–18 weeks of gestation, within a group of 12 patients with foetal DS and 12 patients with uncomplicated pregnancies, who delivered healthy newborns at term, we examined the expression level of 800 miRNAs using the NanoString technology. Our study revealed that there are 6 miRNAs were upregulated (hsa-miR-15a, hsa-let-7d, hsa-miR-142, hsa-miR-23a, hsa-miR-199, hsa-miR-191) and 7 were downregulated (hsa-miR-1290, hsa-miR-1915, hsa-miR30e, hsa-miR-1260, hsa-miR-483, hsa-miR-548, hsa-miR-590) in plasma samples of women with foetal DS syndrome. The genes regulated by identified miRNAs are involved in central nervous system development, congenital abnormalities and heart defects. The results of the present study yielded information on DS-specific miRNA expression signature, which can further help to design a panel of miRNAs as a non-invasive test for DS diagnosis. We believe that identified miRNAs may attend in the pathogenesis of DS and would potentially make a significant role for the future preventive therapies.

1 July 2018 in Chemosphere
Verified
Journal Article
Closed access
MZMonika Zbucka-Kretowska
Monika Zbucka-Kretowska
RZRobert Zbucki
Robert Zbucki
EPEwa Parfieniuk
Ewa Parfieniuk
MMMaciej Maslyk
Maciej Maslyk
ULUrszula Lazarek
Urszula Lazarek
Michal CiborowskiMichal Ciborowski
Michal Ciborowski

3 October 2018 in Expert Review of Proteomics
Verified
Journal Article
Closed access
EPEwa Parfieniuk
Ewa Parfieniuk
MZMonika Zbucka-Kretowska
Monika Zbucka-Kretowska
Michal CiborowskiMichal Ciborowski
Michal Ciborowski
AKAdam Krętowski
Adam Krętowski
CBCoral Barbas
Coral Barbas
Introduction: Metabolomics opens up new avenues for biomarker discovery in different branches of medicine, including perinatology. Chromosomal aberration, preterm delivery (PTD), congenital heart defects, spina bifida, chorioamnionitis, and low birth weight are the main perinatal pathologies. Investigations using untargeted metabolomics have found the candidate metabolites for diagnostic biomarkers. Areas covered: This review describes areas of prenatal diagnosis in which untargeted metabolomics has been used. Data on the disease, type of sample, techniques used, number of samples used in the study, and metabolites obtained including the sign of their regulation are summarized. Expert commentary: Untargeted metabolomics is a powerful tool which can shed a new light on prenatal diagnostics. It helps to discover affected metabolic pathways what may help to reveal disease pathogenesis and propose potential biomarkers. Among others, glycerol and 2- and 3-hydroxybutyrate were proposed as markers of chromosomal aberration. Serum metabolic signature of PTD was characterized by increased lipids and decreased levels of hypoxanthine, tryptophane, and pyroglutamic acid. Lower level lipids and vitamin D3 metabolites together with increased bilirubin level in maternal serum were associated with macrosomia. However, to give a real value to those assays and allow their clinical application multicenter, large cohort validation studies are necessary.

18 May 2017 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
Michal CiborowskiMichal Ciborowski
Michal Ciborowski
JKJoanna Kisluk
Joanna Kisluk
KPKarolina Pietrowska
Karolina Pietrowska
PSPaulina Samczuk
Paulina Samczuk
EPEwa Parfieniuk
Ewa Parfieniuk
JNJacek Niklinski
Jacek Niklinski